CR2

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Ovarian cancer, SLS, Survival, Lymphoma, Fast track (FDA), PTCL, National Cancer Institute, CMC, Clinical trial, Committee, Research, NCI, European School, Bone marrow, AML, GPS, Pembrolizumab, Doctor of Science, Nivolumab, Safety, MRD, CDK9, BLA, Food, CR2, Zanubrutinib, Mesothelioma, BIW, MD, Completeness, WT1, FDA, DLBCL, IDMC, Therapeutic index, Type, Fast Track, Biomarker, BTK, Pharmaceutical industry

The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.

Key Points: 
  • The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
  • The first patient who achieved a complete response continues on the study and remains leukemia-free 9 months post-enrollment.
  • The net proceeds from the offering strengthen the Company’s financial position and will be used for research and development activities, working capital, and general corporate purposes.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million.

IGadgets and CRANNS collaborate on promoting the CRANNS RB6 - Smart Alarm Disc Lock Redefines Two-Wheeler Security

Retrieved on: 
Tuesday, February 13, 2024
Bicycle industry, Motorcycle, GM, RB6, Safety, CR2, Scooter, Wheeler, Movement, Bicycle, Theft

IGadgets has been engaged to help this original start-up market CRANNS RB6 , the revolutionary disc smart lock design for your 2 wheelers.

Key Points: 
  • IGadgets has been engaged to help this original start-up market CRANNS RB6 , the revolutionary disc smart lock design for your 2 wheelers.
  • Introducing CRANNS RB6 Smart Alarm Disc Lock, a meticulously designed solution catering specifically to 2-wheelers such as Vespa, scooters, e-bikes, and bicycles.
  • CRANNS RB6 smart alarm disc lock has a unique C-shaped design that matches any 2-wheeler's disc base so it can work with your Motorcycle, Vespa, Scooter, E-bike and Bicycle.
  • With CRANNS RB6 , you don't just secure your two-wheeler; you invest in cutting-edge technology that provides peace of mind.

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Retrieved on: 
Wednesday, January 3, 2024
Mesothelioma, Therapeutic index, Doctor of Science, Food, Survival, Lymphoma, Bone marrow, BLA, Ovarian cancer, GPS, MRD, FDA, Type, CMC, CR2, MD, Nivolumab, WT1, Clinical trial, SLS, Acute myeloid leukemia, Patient, Safety, PTCL, AML, Pembrolizumab, Pharmaceutical industry

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a corporate webinar at 8:30 am ET.

Key Points: 
  • “2023 was a very productive year for SELLAS,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • Dr. Stergiou continued: “We hope to build on this excellent progress and look forward to multiple clinical milestones that have the potential to create significant value for our shareholders.
  • Meaningful cell killing activity, defined as ≥50% reduction in blasts in the bone marrow, was observed at several dose levels.
  • This study is fully funded by the Company’s partner for SLS009, GenFleet Therapeutics (Shanghai), Inc. and is being conducted in China.

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

Retrieved on: 
Monday, December 4, 2023
Doctor of Science, Survival, Heel, GPS, CR2, Patient safety, MD, Clinical trial, SLS, IDMC, Acute myeloid leukemia, Patient, Safety, AML, Pharmaceutical industry

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC). The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The IDMC also requested that the survival database be updated immediately prior to the next IDMC meeting, which will take place in Q1 2024, and be provided to the IDMC for its review at the meeting.

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC).
  • The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications.
  • “This review comes on the heels of reaching our patient enrollment target, ex-China, and we very much look forward to the IDMC’s next meeting in the first quarter of 2024.
  • The IDMC charter provides for periodic reviews for safety, efficacy, and futility in addition to the interim and final analyses.

SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

Retrieved on: 
Thursday, October 12, 2023
Plasma protein binding, 3D, MD, CR2, Medication, AML, GPS, Acute myeloid leukemia, Doctor of Science, Patient, SLS, Pharmaceutical industry

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided an update on its Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission following second-line salvage therapy (CR2 patients).

Key Points: 
  • The Company expects to complete enrollment in the REGAL study, other than the 20-25 patients anticipated to be enrolled in China, in November 2023.
  • The number of patients needed for the pre-specified interim and final analyses have already been enrolled.
  • The next meeting of the Independent Data Monitoring Committee for the REGAL study is scheduled for the end of November 2023.
  • Importantly, adding approximately 25 patients from China could potentially facilitate drug approval in this significant market, assuming positive data, further yielding additional milestone payments and royalties for SELLAS.”

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

Retrieved on: 
Wednesday, September 27, 2023
Drug delivery, Retina, Injection, CR2, Pediatrics, IgG4-related ophthalmic disease, Sclera, Eye, Geographic atrophy, Quality of life, Intravitreal injection, Inflammation, AAV, Complement, RESEARCH, Administration, C3, Choroid, Stanford University School of Medicine, Patient, CR1, PARK, Entrepreneurship, FDA, Therapy, Emotional dysregulation, Disease, Pharmaceutical industry, Medical device, Vaccine, Ophthalmology, Kriyā, C5

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device. Everads is a private biotech company that has developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space, an anatomical compartment located between the sclera and choroid that traverses the circumference of the posterior segment of the eye. Suprachoroidal delivery is an emerging, non-surgical route of administration in ophthalmology. Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.

Key Points: 
  • Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.
  • The transaction enables Kriya’s access to Everads’ suprachoroidal delivery technology to deliver multiple prespecified gene therapy product candidates for several ophthalmic diseases, including those involving the complement cascade.
  • “I am quite optimistic and convinced that innovative therapies will continue to improve the lives of people with geographic atrophy and other serious ophthalmic diseases.
  • A gene therapy targeting the C3 and C5 pathways delivered by a suprachoroidal injection may be a significant improvement in the treatment of geographic atrophy.”

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

Retrieved on: 
Tuesday, August 22, 2023
CR2, GPS, IDMC, Survival, Clinical trial, Acute myeloid leukemia, AML, Doctor of Science, SLS, MD, Patient, Patient safety, Safety, Pharmaceutical industry

NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC). The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. While the interim analysis is event driven per the protocol (60 events), based upon the Company’s statistical assumptions, the interim analysis is expected to occur by late 2023 or early 2024. The Company anticipates that enrollment in the study will be completed during Q4 2023. The IDMC is scheduled to meet again within Q4 2023.

Key Points: 
  • The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications.
  • The Company anticipates that enrollment in the study will be completed during Q4 2023.
  • REGAL is a Phase 3 open-label registrational clinical trial for GPS in AML patients who have achieved complete remission following second-line salvage therapy (CR2 patients).
  • The IDMC charter provides for periodic reviews for safety, efficacy, and futility in addition to the interim and final analyses.

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
BAT, Maintenance, CR2, GPS, University, D, Organic Process Research & Development, Venetoclax, Safety, Mesothelioma, IDMC, American Society of Clinical Oncology, Clinical research associate, Clinical trial, Survival, University of North Carolina, Research, Second, Acute myeloid leukemia, MD Anderson Cancer Center, ASCO, AML, Azacitidine, Bristol Myers Squibb, Doctor of Science, SLS, Patient, Annual general meeting, CR, WT1, Merck & Co., Merck, Ovarian cancer, Merck Sharp & Dohme Federal Credit Union, CDK9, Society, MPM, Nivolumab, Bone marrow, Pharmaceutical industry, Birth control, MD

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023.

Key Points: 
  • NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023.
  • The next routine IDMC meeting is scheduled for the third quarter of 2023.
  • SELLAS expects to receive milestone payments totaling $13.0 million from 3D Medicines by the end of the third quarter of 2023.
  • Financial Results for the Second Quarter 2023:
    R&D Expenses: Research and development expenses for the second quarter of 2023 were $5.9 million, compared to $5.5 million for the same period in 2022.

KEENON Robotics Emerges as Market Leader Once Again with Over 60% Market Share

Retrieved on: 
Tuesday, July 18, 2023
IDC, CR2, United Nations, Education, Projections of population growth, Perception, Ageing, USD, Emerging technologies, Foodservice, Robotics, Growth, City, United, International Data Group, Mobile phone

SHANGHAI, July 18, 2023 /PRNewswire/ -- KEENON Robotics, a global leader in cutting-edge service robots and solutions, has once again emerged as the market leader in China's commercial service robots for the catering industry.

Key Points: 
  • SHANGHAI, July 18, 2023 /PRNewswire/ -- KEENON Robotics, a global leader in cutting-edge service robots and solutions, has once again emerged as the market leader in China's commercial service robots for the catering industry.
  • According to the latest report by renowned market research institution IDC (International Data Corporation), KEENON Robotics secured an impressive 60.4% market share in 2022, marking the company's highest-ever share and a significant increase from 48.6% in 2021.
  • Furthermore, the CR2 (concentration ratio of the two major players in the market) of the catering service robot market achieves an impressive market share of 83.6%, of which KEENON Robotics dominates over 60%.
  • While Gausium leads the cleaning industry, KEENON Robotics that has topped in the catering industry holds over 22% of the overall market share of commercial service robots in China.